1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11. International Agency for Research on Cancer;Accessed February 13th, 2018.
http://globocan.iarc.fr.
2. National Cancer Information Center. Ministry of Health and Welfare. Cancer statistics. Accessed February 13th, 2018.
https://www.cancer.go.kr/.
3. Lee KS, Chang HS, Lee SM, Park EC. Economic burden of cancer in Korea during 2000-2010. Cancer Res Treat. 2015; 47:387–398. PMID:
25672582.

4. Shin HR, Won YJ, Jung KW, Kong HJ, Yim SH, Lee JK, et al. Nationwide cancer incidence in Korea, 1999~2001: first result using the national cancer incidence database. Cancer Res Treat. 2005; 37:325–331. PMID:
19956367.

5. Fay MP, Tiwari RC, Feuer EJ, Zou Z. Estimating average annual percent change for disease rates without assuming constant change. Biometrics. 2006; 62:847–854. PMID:
16984328.

6. Kim HJ, Luo J, Chen HS, Green D, Buckman D, Byrne J, et al. Improved confidence interval for average annual percent change in trend analysis. Stat Med. 2017; 36:3059–3074. PMID:
28585245.

7. Kim Z, Min SY, Yoon CS, Jung KW, Ko BS, Kang E, et al. The basic facts of Korean breast cancer in 2012: results from a nationwide survey and breast cancer registry database. J Breast Cancer. 2015; 18:103–111. PMID:
26155285.

8. Min SY, Kim Z, Hur MH, Yoon CS, Park EH, Jung KW, et al. The basic facts of Korean breast cancer in 2013: results of a nationwide survey and breast cancer registry database. J Breast Cancer. 2016; 19:1–7. PMID:
27066090.

9. Park EH, Min SY, Kim Z, Yoon CS, Jung KW, Nam SJ, et al. Basic facts of breast cancer in Korea in 2014: the 10-year overall survival progress. J Breast Cancer. 2017; 20:1–11. PMID:
28382089.

10. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. 2013. Lyon: International Agency for Research on Cancer;2014.
12. DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin. 2014; 64:52–62. PMID:
24114568.

13. Ernster VL, Ballard-Barbash R, Barlow WE, Zheng Y, Weaver DL, Cutter G, et al. Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst. 2002; 94:1546–1554. PMID:
12381707.

15. Saika K, Sobue T. Epidemiology of breast cancer in Japan and the US. Japan Med Assoc J. 2009; 52:39–44.
16. Zeng H, Zheng R, Zhang S, Zou X, Chen W. Female breast cancer statistics of 2010 in China: estimates based on data from 145 population-based cancer registries. J Thorac Dis. 2014; 6:466–470. PMID:
24822104.
17. DeSantis C, Howlader N, Cronin KA, Jemal A. Breast cancer incidence rates in U.S. women are no longer declining. Cancer Epidemiol Biomarkers Prev. 2011; 20:733–739. PMID:
21357727.

18. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med. 2010; 134:e48–e72. PMID:
20586616.
19. Anderson WF, Rosenberg PS, Petito L, Katki HA, Ejlertsen B, Ewertz M, et al. Divergent estrogen receptor-positive and -negative breast cancer trends and etiologic heterogeneity in Denmark. Int J Cancer. 2013; 133:2201–2206. PMID:
23616071.

20. Yang XR, Chang-Claude J, Goode EL, Couch FJ, Nevanlinna H, Milne RL, et al. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst. 2011; 103:250–263. PMID:
21191117.
21. Colditz GA, Rosner BA, Chen WY, Holmes MD, Hankinson SE. Risk factors for breast cancer according to estrogen and progesterone receptor status. J Natl Cancer Inst. 2004; 96:218–228. PMID:
14759989.

22. Fancellu A. Considerations arising from requests from patients for a bilateral mastectomy who are eligible for breast-conserving surgery: factors weighing for and against performing the operation. Oncol Lett. 2016; 12:764–766. PMID:
27347213.

23. Xia C, Schroeder MC, Weigel RJ, Sugg SL, Thomas A. Rate of contralateral prophylactic mastectomy is influenced by preoperative MRI recommendations. Ann Surg Oncol. 2014; 21:4133–4138. PMID:
24934585.

24. Heil J, Rauch G, Szabo AZ, Garcia-Etienne CA, Golatta M, Domschke C, et al. Breast cancer mastectomy trends between 2006 and 2010: association with magnetic resonance imaging, immediate breast reconstruction, and hospital volume. Ann Surg Oncol. 2013; 20:3839–3846. PMID:
23838917.

25. Miller BT, Abbott AM, Tuttle TM. The influence of preoperative MRI on breast cancer treatment. Ann Surg Oncol. 2012; 19:536–540. PMID:
21751044.

26. Fisher CS, Martin-Dunlap T, Ruppel MB, Gao F, Atkins J, Margenthaler JA. Fear of recurrence and perceived survival benefit are primary motivators for choosing mastectomy over breast-conservation therapy regardless of age. Ann Surg Oncol. 2012; 19:3246–3250. PMID:
22833001.

27. Mahmood U, Hanlon AL, Koshy M, Buras R, Chumsri S, Tkaczuk KH, et al. Increasing national mastectomy rates for the treatment of early stage breast cancer. Ann Surg Oncol. 2013; 20:1436–1443. PMID:
23135312.

28. Lee EA, Shin J, Hwang EJ, Lee JW. Breast and cervical cancer screening behavior in female cancer survivors: the Korea National Health and Nutrition Examination Survey, 2007-2012. Korean J Fam Med. 2017; 38:116–121. PMID:
28572886.

30. DeSantis CE, Ma J, Goding Sauer A, Newman LA, Jemal A. Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J Clin. 2017; 67:439–448. PMID:
28972651.
